



ASX Announcement

05 December 2024

Cambium Bio Successfully Closes A\$3.0M Financing Round

Sydney, Australia; 5 December 2024: Cambium Bio Limited (ASX:CMB) (**Cambium Bio, Cambium or Company**), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to announce the successful completion of a A\$3.0 million capital raising.

Key Highlights:

- Capital raising of A\$3.0 million completed at A\$0.4637 per share, representing a 25% discount to the 5-day Volume Weighted Average Price (VWAP) up to and including 2 December 2024
- Strong support from new strategic investor AventaCell Biomedical Corp and existing major shareholder Zheng Yang Biomedical Technology
- Additional participation from Cambium Bio directors, CEO, and Australian institutional and sophisticated investors
- Proceeds to advance Phase 3 clinical development of Elate Ocular® for dry eye disease

The capital raising, which was approved by shareholders at the Annual General Meeting held on 26 November 2024, comprises:

- A\$1.5 million strategic investment from AventaCell Biomedical Corp
- A\$0.25 million investment from Zheng Yang Biomedical Technology
- A\$0.146 million from Cambium Bio directors
- A\$1.054 million from Cambium Bio CEO, Australian institutional, sophisticated and other investors

Cambium Bio CEO, **Karolis Rosickas**, commented: "We are delighted with the strong support received in this capital raising, particularly from AventaCell Biomedical Corp as a new strategic investor. AventaCell's global leadership in cell culture supplements using our human platelet technology makes them an ideal partner as we advance our therapeutic programs. The participation of our existing major shareholder ZYBT, along with directors and management, demonstrates continued confidence in our strategy and clinical and commercial potential of Elate Ocular®."

Lodge Corporate acted as Lead Manager for the Placement with Australian institutional and sophisticated investors.

Regulatory Approvals

The investments by AventaCell, ZYBT, and Cambium directors will be subject to shareholder approval at a General Meeting expected to be held in February 2025. This approval is required under the Corporations Act takeover provisions and ASX Listing Rule 10.11 due to the existing relationships between these parties. The relevant combined interest of AventaCell, ZYBT, and Dr Sebastian Tseng would increase from 24.5% to 37.8% under the Corporations Act takeover provisions. Detailed information about these matters will be provided in the Notice of Meeting to be distributed to shareholders.

Use of Funds

The proceeds will primarily support the advancement of Elate Ocular® through its registration-enabling Phase 3 clinical trials for dry eye disease, which are planned to commence in calendar Q2 2025. The funds will also provide working capital for the Company's ongoing operations.

About AventaCell Biomedical Corp

AventaCell is a US-based life sciences company developing novel human-derived products for use in cell culture and tissue regeneration. The company is the global leader in cell culture supplements manufactured using Cambium Bio's proprietary human platelet technology under an existing license agreement. For more information, visit <https://www.atcbiomed.com>.

- ENDS -

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:

Helen Leung
Corporate Secretary
info@cambium.bio
1 300 995 098